Characterization of an envelope mutant of HIV-1 that interferes with viral infectivity

被引:25
|
作者
Chen, SSL
Ferrante, AA
Terwilliger, EF
机构
[1] NEW ENGLAND DEACONESS HOSP,HEMATOL ONCOL RES LABS,DIV HEMATOL ONCOL,BOSTON,MA 02215
[2] HARVARD UNIV,SCH MED,BOSTON,MA 02215
[3] ACAD SINICA,INST BIOMED SCI,TAIPEI,TAIWAN
关键词
D O I
10.1006/viro.1996.0654
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A mutant human immunodeficiency virus (HIV-1) provirus encoding an envelope (Env) protein with a truncated transmembrane protein cytoplasmic domain was defective for replication. Coexpression of the mutant with a wild-type (wt) HIV-1 provirus potently inhibited the production of infectious virus. The maximum inhibitory effect was reached when the ratio of mutant to wt proviral DNA was 2:1, This transdominant defect in infectivity conferred by the mutant Env did not appear to involve the late steps of virus replication, since the synthesis, precursor processing, and intracellular transport of the Env proteins were not blocked; nor did it prevent the incorporation of the envelope proteins into virions or the subsequent release of the virus. Although the mutant Env protein still retained syncytia-forming ability, the truncated protein was unable to mediate cell-to-cell transmission of the virus. Moreover, coexpression with the mutant effectively inhibited the ability of the wt Env to mediate cell-to-cell transmission. The mutant Env protein formed a complex with the wt protein when they were coexpressed, producing heterooligomeric structures which appeared to be severely defective in an early, post-CD4 binding step of the virus life cycle despite the inclusion of wt Env in the complexes. (C) 1996 Academic Press. Inc.
引用
收藏
页码:260 / 268
页数:9
相关论文
共 50 条
  • [21] HIV-1 Diversity in the Envelope Glycoproteins: Implications for Viral Entry Inhibition
    Luvison Araujo, Leonardo Augusto
    Almeida, Sabrina E. M.
    VIRUSES-BASEL, 2013, 5 (02): : 595 - 604
  • [22] Antiretroviral therapy targeting HIV-1 viral infectivity factor; in silico approach
    Karau, Muriira G.
    Karau, Bundi P.
    RETROVIROLOGY, 2009, 6
  • [23] Viral Infectivity Factor: A Novel Therapeutic Strategy to Block HIV-1 Replication
    Yang, Guliang
    Xiong, Xujie
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 1047 - 1055
  • [24] Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1
    Tanaka, M
    Ueno, T
    Nakahara, T
    Sasaki, K
    Ishimoto, A
    Sakai, H
    VIROLOGY, 2003, 311 (02) : 316 - 325
  • [25] Effect of partial inhibition of HIV-1 polyprotein processing and maturation on viral infectivity
    Mueller, B.
    Anders, M.
    Tervo, H-M
    Keppler, O. T.
    Kraeusslich, H.-G.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A117 - A117
  • [26] Antiretroviral therapy targeting HIV-1 viral infectivity factor; in silico approach
    Muriira G Karau
    Bundi P Karau
    Retrovirology, 6
  • [27] The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association
    Lu, Wuxun
    Chen, Shuliang
    Yu, Jingyou
    Behrens, Ryan
    Wiggins, Joshua
    Sherer, Nathan
    Liu, Shan-Lu
    Xiong, Yong
    Xiang, Shi-Hua
    Wu, Li
    JOURNAL OF VIROLOGY, 2019, 93 (07)
  • [28] Expression and characterization of HIV-1 envelope glycoprotein in Pichia pastoris
    Zhao Li-hui
    Yu Xiang-hui
    Jiang Chun-lai
    Wu Yong-ge
    Shen Jia-cong
    Kong Wei
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2008, 24 (03) : 316 - 321
  • [29] SALIVA INHIBITS HIV-1 INFECTIVITY
    FOX, PC
    WOLFF, A
    YEH, CK
    ATKINSON, JC
    BAUM, BJ
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1988, 116 (06): : 635 - 637
  • [30] Optimization of HIV-1 infectivity assays
    Jones, Jennifer
    Whitford, William
    Wagner, Frederic
    Kutsch, Olaf
    BIOTECHNIQUES, 2007, 43 (05) : 589 - +